Erik Sparve

Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol

Ulf Diczfalusy, Tobias Bäckström, Erik Sparve et al. · Clinical Pharmacology & Therapeutics · 2008 · 131 citations

Human Exposure to Triclosan via Toothpaste does not change CYP3A4 Activity or Plasma Concentrations of Thyroid Hormones

Mats Allmyr, Georgios Panagiotidis, Erik Sparve et al. · Basic & Clinical Pharmacology & Toxicology · 2009 · 95 citations · Full text

Cyp3a4 Activity, Toxicological Mechanism, Everyday Exposure +16

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares

Kenneth G. Saag, Puja Khanna, Robert T. Keenan et al. · Arthritis & Rheumatology · 2021 · 82 citations · Full text

Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study

Ute Spiekerkoetter, María L. Couce, Anibh M. Das et al. · The Lancet Diabetes & Endocrinology · 2021 · 33 citations

Medicine, Multicentre Study, Long-term Safety +1

Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ₄₀and Aβ₄₂following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers

Angelica Quartino, Gunilla Huledal, Erik Sparve et al. · Clinical Pharmacology in Drug Development · 2014 · 17 citations